ArticleDiabetes care2022
Remnant Cholesterol and Its Visit-to-Visit Variability Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes: Findings From the ACCORD Cohort.
Article in Diabetes care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 73 citations in OpenAlex.
- Discordance between remnant cholesterol and low-density lipoprotein cholesterol predicts incident hypertension: a 9-year prospective cohort study in Chinese adults.BMC cardiovascular disorders · 2026Article
- Association between remnant cholesterol inflammation index and erectile dysfunction among U.S. adults: a cross-sectional study.Translational andrology and urology · 2026Article
- Triglyceride-Rich Lipoproteins and Inflammation: Independent and Synergistic Roles in Cardiovascular Disease.Current atherosclerosis reports · 2026Review
- A Narrative Review of Remnant Cholesterol as an Independent Atherogenic Lipoprotein in Type 2 Diabetes: Pathophysiology and Clinical Implications.Therapeutics and clinical risk management · 2026Review
- Association of cumulative remnant cholesterol exposure with adverse outcomes after PCI in acute ST-segment elevation myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- Remnant cholesterol: a risk stratification aid for coronary artery stenosis severity in patients with type 2 diabetes.Frontiers in medicine · 2026Article
- Visceral fat area and visceral-to-subcutaneous fat ratio are more strongly associated with residual cholesterol than conventional anthropometric indices in adults with type 2 diabetes.Frontiers in endocrinology · 2026Article
- Exploring the relationship between remnant cholesterol and diabetic kidney disease in Chinese type 2 diabetes patients.Frontiers in nutrition · 2026Article
- Emerging importance of remnant cholesterol compared with low-density lipoprotein cholesterol in cardiovascular risk assessment.Scientific reports · 2025Article
- Remnant cholesterol associated with contrast-induced acute kidney injury in patients with ST-segment elevation myocardial infarction following percutaneous coronary intervention.Scientific reports · 2025Article
- Residual cholesterol inflammatory index and its prognostic role in mortality among individuals with cardiovascular-kidney-metabolic syndrome stages 0-3 based on U.S. and Chinese national cohorts.European journal of medical research · 2025Article
- Longitudinal correlation between cumulative remnant cholesterol inflammatory index and incident diabetes.Diabetology & metabolic syndrome · 2025Article
- Combined effects of insulin resistance and dyslipidaemia on cardiometabolic multimorbidity in Chinese middle-age and older adults: a longitudinal cohort study.Scientific reports · 2025Observational
- Cumulative remnant cholesterol and major adverse cardiovascular events among adults with type 2 diabetes.American journal of preventive cardiology · 2025Article
- Association of long-term remnant cholesterol with the incidence of chronic kidney disease in a high-risk population.Hormones (Athens, Greece) · 2025Article
- Metabolic score for insulin resistance is associated with adverse cardiovascular events in patients with type 2 diabetes.World journal of diabetes · 2025Article
- Risk of remnant cholesterol and chronic obstructive pulmonary disease: a mendelian randomization study.Journal of thoracic disease · 2025Article
- Remnant cholesterol, high-sensitivity C-reactive protein, and risk of incident coronary heart disease among patients with chronic kidney disease based on UK biobank.Nutrition & metabolism · 2025Article
- Remnant cholesterol predicts the development of type 2 diabetes in patients with nonalcoholic fatty liver disease.Diabetology & metabolic syndrome · 2025Article
- Remnant-to-LDL cholesterol discordance as a predictor of thromboembolic events in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia AF project III (MAFP-III) cohort study.Cardiovascular diabetology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRemnant cholesterol (remnant-C) predicts atherosclerotic cardiovascular disease, regardless of LDL-cholesterol (LDL-C) levels. This study assessed the associations between remnant-C and cardiovascular outcomes in type 2 diabetes. RESEARCH DESIGN AND
methodsThis post hoc analysis of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial used patient (type 2 diabetes >3 months) remnant-C and major adverse cardiovascular event (MACE) data from the study database. The associations between remnant-C and MACEs were evaluated using Cox proportional hazards regression analyses. We examined the relative MACE risk in remnant-C versus LDL-C discordant/concordant groups using clinically relevant LDL-C targets by discordance analyses.
resultsThe baseline analysis included 10,196 participants, with further visit-to-visit variability analysis including 9,650 participants. During follow-up (median, 8.8 years), 1,815 patients (17.8%) developed MACEs. After adjusting for traditional cardiovascular risk factors, each 1-SD increase in remnant-C was associated with a 7% higher MACE risk (hazard ratio [HR] 1.07, 95% CI 1.02-1.12, P = 0.004). In the fully adjusted model, the visit-to-visit remnant-C variability calculated using logSD (HR 1.41, 95% CI 1.18-1.69, P < 0.001) and logARV (HR 1.45, 95% CI 1.22-1.73, P < 0.001) was associated with MACEs. Residual lipid risk (remnant-C ≥31 mg/dL) recognized individuals at a higher MACE risk, regardless of LDL-C concentrations. Within each LDL-C subgroup (>100 or ≤100 mg/dL), high baseline remnant-C was associated with a higher MACE risk (HR 1.37, 95% CI 1.09-1.73, P = 0.007; HR 1.22, 95% CI 1.04-1.41, P = 0.015, respectively).
conclusionsRemnant-C levels were associated with MACEs in patients with type 2 diabetes independent of LDL-C, and visit-to-visit remnant-C variability helped identify those with higher cardiovascular risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.